7A5L
tructure of DYRK1A in complex with compound 24
7A5L の概要
エントリーDOI | 10.2210/pdb7a5l/pdb |
関連するPDBエントリー | 7a4o 7a4r 7a4s 7a4w 7a4z 7a51 7a52 7a53 7a55 7a5b 7a5d |
分子名称 | Dual specificity tyrosine-phosphorylation-regulated kinase 1A, 4-[2-methyl-4-(thiophen-3-ylmethoxy)-7~{H}-pyrrolo[2,3-d]pyrimidin-5-yl]pyridin-2-amine, CHLORIDE ION, ... (4 entities in total) |
機能のキーワード | serine/threonine-protein kinase, phosphoprotein, kinase, sbdd, fbld, small molecule inhibitor, transferase |
由来する生物種 | Homo sapiens (Human) |
タンパク質・核酸の鎖数 | 1 |
化学式量合計 | 42019.98 |
構造登録者 | |
主引用文献 | Lee Walmsley, D.,Murray, J.B.,Dokurno, P.,Massey, A.J.,Benwell, K.,Fiumana, A.,Foloppe, N.,Ray, S.,Smith, J.,Surgenor, A.E.,Edmonds, T.,Demarles, D.,Burbridge, M.,Cruzalegui, F.,Kotschy, A.,Hubbard, R.E. Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B. J.Med.Chem., 64:8971-8991, 2021 Cited by PubMed Abstract: The serine/threonine kinase DYRK1A has been implicated in regulation of a variety of cellular processes associated with cancer progression, including cell cycle control, DNA damage repair, protection from apoptosis, cell differentiation, and metastasis. In addition, elevated-level DYRK1A activity has been associated with increased severity of symptoms in Down's syndrome. A selective inhibitor of DYRK1A could therefore be of therapeutic benefit. We have used fragment and structure-based discovery methods to identify a highly selective, well-tolerated, brain-penetrant DYRK1A inhibitor which showed in vivo activity in a tumor model. The inhibitor provides a useful tool compound for further exploration of the effect of DYRK1A inhibition in models of disease. PubMed: 34143631DOI: 10.1021/acs.jmedchem.1c00024 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2.1 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
![ダウンロード](/newweb/media/icons/dl.png)